Patents by Inventor Christopher Bauer

Christopher Bauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
    Patent number: 6361976
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 26, 2002
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Methods of using multivariant IL-3 hematopoiesis fusion protein
    Patent number: 6361977
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 26, 2002
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
    Patent number: 6153183
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: November 28, 2000
    Assignee: G. D. Searle & Company
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan M. Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Human interleukin-3 (IL-3) variant fusion proteins
    Patent number: 6132991
    Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 17, 2000
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production
    Patent number: 6093395
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF's), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 25, 2000
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Ex vivo expansion of hematopoietic cells using interleukin-3 (IL-3) variant fusion proteins
    Patent number: 6074639
    Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
    Type: Grant
    Filed: November 15, 1995
    Date of Patent: June 13, 2000
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
    Patent number: 6066318
    Abstract: Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional hematopoietic receptor agonists proteins and methods of using the multi-functional hematopoietic receptor agonists proteins.
    Type: Grant
    Filed: April 4, 1997
    Date of Patent: May 23, 2000
    Assignee: G.D. Searle & Co.
    Inventors: Yiqing Feng, Nicholas R. Staten, Charles M. Baum, Neena L. Summers, Maire Helena Caparon, S. Christopher Bauer, Linda L. Zurfluh, John P. McKearn, Barbara K. Klein, Stephen C. Lee, Charles A. McWherter, Judith G. Giri
  • Co-administration of interleukin-3 mutant polypeptides with CSF's for multi-lineage hematopoietic cell production
    Patent number: 6060047
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 9, 2000
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Multivariant human IL-3 fusion proteins and their recombinant production
    Patent number: 6057133
    Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin, hematopoietic growth factor or IL-3 variant. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: May 2, 2000
    Assignee: G. D. Searle
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Therapeutic uses of interleukin-3 (IL-3) multiple mutation polypeptides
    Patent number: 6051217
    Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 18, 2000
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Frameless stereotactic arm apparatus and method of using same
    Patent number: 6035228
    Abstract: An imaging apparatus (18) includes a frameless stereotactic arm apparatus (30) including a first base portion (42) mounted in a fixed relationship to the imaging device. A second free end (40) of the arm assembly is adapted to move into varied positions near a specimen disposed on the imaging apparatus. At least one pivot joint (44, 48, 52, 56, 60) is provided between the first base portion and the free end of the arm for permitting selective relevant movement between the arm members. Electro-mechanical and electro-magnetic brake devices are provided at respective joints to selectively lock the free end of the arm assembly to the base portion. The brakes are responsive to a brake command signal (210) generated by the imaging device. A low pass filter (240) conditions the brake command signal to substantially eliminate high frequency electromagnetic switching noise in the stereotactic arm.
    Type: Grant
    Filed: November 28, 1997
    Date of Patent: March 7, 2000
    Assignee: Picker International, Inc.
    Inventors: Jeffrey H. Yanof, Ronald B. Sharpless, David Jeri, Christopher Bauer, Daniel S. Furst
  • Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
    Patent number: 6030812
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 29, 2000
    Assignee: G. D. Searle & Company
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan M. Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
    Patent number: 6022535
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 8, 2000
    Assignee: G. D. Searle & Company
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helen Caparon, Alan M. Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
  • Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
    Patent number: 6017523
    Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain one to three amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (corresponding to residues 119 to 133) have been deleted from the C-terminus, and which also contain one to three amino acid substitutions in the polypeptide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 25, 2000
    Assignee: G.D. Searle & Co.
    Inventors: S. Christopher Bauer, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, John Patrick McKearn, Peter Olafs Olins
  • Co-administration of interleukin-3 mutants with colony stimulating factors
    Patent number: 5997857
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 7, 1999
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines
    Patent number: 5997860
    Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with a other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
    Type: Grant
    Filed: November 15, 1995
    Date of Patent: December 7, 1999
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Interchangeable guidance devices for C.T. assisted surgery and method of using same
    Patent number: 5957933
    Abstract: A stereotactic guide apparatus 100 is provided for use with a CT scanner device 18 for guiding the entry of a probe into a patient's body. The CT scanner device is provided with a stereotactic arm member 30 having a first base end 42 connected to the CT scanner device 18 and a second free end 40 movable relative to the CT scanner device. The stereotactic surgical instrument guide apparatus includes a first end effector member 106 including a guide channel 152 defining a probe insertion path 150. The surgical instrument guidance device further includes a second end effector member 104 on the free end of the stereotactic arm member and including a laser light source 108 generating a light guide beam along the probe insertion path 150.
    Type: Grant
    Filed: November 28, 1997
    Date of Patent: September 28, 1999
    Assignee: Picker International, Inc.
    Inventors: Jeffrey H. Yanof, Laura L. Goldstein, Fred C. Jensen, James C. Foster, Christopher Bauer
  • Therapeutic methods using fusion proteins between interleukin-3 (IL-3) variants and other hematopoietic factors
    Patent number: 5858347
    Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 12, 1999
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Recombinant human interleukin-3 (IL-3) multiple mutation polypeptides
    Patent number: 5817486
    Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 6, 1998
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, John Patrick McKearn, Peter Olafs Olins
  • Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
    Patent number: 5772992
    Abstract: The invention provides compositions comprising a human interleukin-3 (hIL-3) variant or mutant protein (mutein) and another colony stimulating factor, cytokine, lymphokine, interleukin, or hematopoietic growth factor. The compositions are useful for the therapeutic co-administration of the proteins, as for example in hematopoietic reconstitution. factors or IL-3 variants.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: June 30, 1998
    Assignee: G.D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas